ETFChannel.com
EXEL Description — Exelixis Inc

Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.

Company Name: 
Exelixis Inc
Website: 
www.exelixis.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding EXEL: 
75
Total Market Value Held by ETFs: 
$956,930,460.9
Total Market Capitalization: 
$5,210,000,000
% of Market Cap. Held by ETFs: 
18.37%
 ETF   EXEL Weight   EXEL Amount 
 VTI   0.01%   $151,823,277         
 IJH   0.27%   $149,212,150         
 VB   0.12%   $130,015,235         
 VBK   0.29%   $77,010,422         
 VXF   0.09%   $69,570,462         
 XBI   1.00%   $67,306,300         
 MDY   0.27%   $43,727,138         
 FBT   2.59%   $32,572,156         
 FXH   1.65%   $23,071,380         
 XT   0.70%   $18,912,313         
List of all 75 ETFs holding EXEL »
Quotes delayed 20 minutes

Email EnvelopeFree EXEL Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (3.55 out of 4)
54th percentile
(ranked higher than approx. 54% of all stocks covered)

Analysts Forecast:
EXEL Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding EXEL | Exelixis Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.